Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZG005 + gecacitinib
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
- ZG005 + gecacitinib is an experimental combination of two drugs: ZG005, a bispecific antibody that simultaneously targets PD-1 (Programmed cell death protein 1) and TIGIT (T cell immunoreceptor with Ig and ITIM domains), and gecacitinib, a small molecule inhibitor of Janus kinases (JAK1, JAK2, JAK3, and TYK2) and ACVR1. - ZG005 works by blocking both the PD-1 and TIGIT immune checkpoints, aiming to synergistically activate T cells and enhance anti-tumor immune responses. - Gecacitinib inhibits the JAK-STAT pathway and ACVR1, reducing inflammation, improving anemia by downregulating hepcidin, improving iron metabolism, and reducing splenomegaly. - Both drugs are under clinical development by Suzhou Zelgen Biopharmaceuticals, primarily for oncological and hematological indications such as advanced solid tumors and myelofibrosis[1][2][4][5][6].
- Brand names
- Nilvanstomig
- Other names
- ZG005 + jaktinib
02
Targets
JAK2 (Janus kinase 2)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on ZG005 + gecacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZG005 + gecacitinib.